• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review.糖尿病患者发生重症 COVID-19 的预测因素:一项多中心综述。
Endocr Pract. 2021 Aug;27(8):842-849. doi: 10.1016/j.eprac.2021.05.011. Epub 2021 Jun 6.
2
Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System.在学术医疗体系中,与新冠疫情结果的种族/民族差异相关的特征。
JAMA Netw Open. 2020 Oct 1;3(10):e2025197. doi: 10.1001/jamanetworkopen.2020.25197.
3
Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes.在糖尿病患者中,门诊或住院血糖控制与 COVID-19 疾病严重程度或死亡率之间没有关联。
BMJ Open Diabetes Res Care. 2021 May;9(1). doi: 10.1136/bmjdrc-2021-002203.
4
Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City.COVID-19 成年住院患者死亡率的预测因素:来自纽约市的回顾性队列研究。
West J Emerg Med. 2020 Jul 8;21(4):779-784. doi: 10.5811/westjem.2020.6.47919.
5
A Retrospective Study of COVID-19-Related Urgent Medical Visits and Hospitalizations After Outpatient COVID-19 Diagnosis in the US.美国门诊新冠病毒诊断后与新冠相关的紧急医疗就诊和住院的回顾性研究。
Adv Ther. 2021 Jun;38(6):3185-3202. doi: 10.1007/s12325-021-01742-6. Epub 2021 May 7.
6
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
8
Clinical Characteristics and Outcomes of Patients With Diabetes Admitted for COVID-19 Treatment in Dubai: Single-Centre Cross-Sectional Study.迪拜因 COVID-19 住院治疗的糖尿病患者的临床特征和结局:单中心横断面研究。
JMIR Public Health Surveill. 2020 Dec 7;6(4):e22471. doi: 10.2196/22471.
9
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间,未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
10
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.二肽基肽酶-4(DPP-4)抑制剂与 2019 年冠状病毒病(COVID-19)患者死亡率:系统评价、荟萃分析和荟萃回归。
Diabetes Metab Syndr. 2021 May-Jun;15(3):777-782. doi: 10.1016/j.dsx.2021.03.027. Epub 2021 Apr 1.

引用本文的文献

1
Epidemiological topology data analysis links severe COVID-19 to RAAS and hyperlipidemia associated metabolic syndrome conditions.流行病学拓扑数据分析将严重 COVID-19 与 RAAS 和高血脂相关的代谢综合征状况联系起来。
Bioinformatics. 2024 Jun 28;40(Suppl 1):i199-i207. doi: 10.1093/bioinformatics/btae235.
2
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.抗高血糖药物对 COVID-19 的影响:来自观察性研究的荟萃分析和系统评价。
Ther Innov Regul Sci. 2024 Jul;58(4):773-787. doi: 10.1007/s43441-024-00633-6. Epub 2024 Apr 29.
3
Risk and predictors of severity and mortality in patients with type 2 diabetes and COVID-19 in Dubai.迪拜2型糖尿病合并新冠肺炎患者病情严重程度及死亡率的风险与预测因素
World J Diabetes. 2023 Aug 15;14(8):1259-1270. doi: 10.4239/wjd.v14.i8.1259.
4
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.卡司瑞韦单抗+伊德维单抗加速症状缓解,改善了易感抗体和风险特征患者的 COVID-19 结局。
Sci Rep. 2023 Aug 7;13(1):12784. doi: 10.1038/s41598-023-39681-7.
5
Targeting patients for early COVID-19 therapy; Pre-infection metabolic dysfunction, polycystic ovary syndrome and risk of severe disease in patients under 65: A Massachusetts community-based observational study.针对 COVID-19 早期治疗的患者;感染前代谢功能障碍、多囊卵巢综合征和 65 岁以下患者疾病严重程度的风险:马萨诸塞州社区观察性研究。
PLoS One. 2023 Jun 15;18(6):e0287430. doi: 10.1371/journal.pone.0287430. eCollection 2023.
6
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.糖尿病的风险表型与 COVID-19 严重程度和死亡的关系:一项实时系统评价和荟萃分析的更新。
Diabetologia. 2023 Aug;66(8):1395-1412. doi: 10.1007/s00125-023-05928-1. Epub 2023 May 19.
7
Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients with Diabetes Hospitalized With COVID-19.2019冠状病毒病住院糖尿病患者的血糖控制评估及重症和死亡预测因素
J Community Hosp Intern Med Perspect. 2022 Nov 7;12(6):27-34. doi: 10.55729/2000-9666.1127. eCollection 2022.
8
Correlation Between HbA1c Levels and Mortality Rates in Hospitalized COVID-19 Patients.新型冠状病毒肺炎住院患者糖化血红蛋白水平与死亡率的相关性
Cureus. 2022 Nov 10;14(11):e31347. doi: 10.7759/cureus.31347. eCollection 2022 Nov.
9
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.COVID-19 合并 2 型糖尿病患者入院前使用降糖药物与死亡率的meta 分析
Metabolism. 2022 Jun;131:155196. doi: 10.1016/j.metabol.2022.155196. Epub 2022 Mar 31.
10
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.二肽基肽酶-4(DPP-4)抑制剂与 COVID-19 患者死亡率降低相关——一项系统评价和荟萃分析。
Prim Care Diabetes. 2022 Feb;16(1):162-167. doi: 10.1016/j.pcd.2021.12.008. Epub 2021 Dec 13.

本文引用的文献

1
The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.降血脂药物非诺贝特在细胞培养模型中显著降低新冠病毒感染率。
Front Pharmacol. 2021 Aug 6;12:660490. doi: 10.3389/fphar.2021.660490. eCollection 2021.
2
Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City.评估纽约市 COVID-19 患者住院和死亡的种族/民族差异。
JAMA Netw Open. 2020 Dec 1;3(12):e2026881. doi: 10.1001/jamanetworkopen.2020.26881.
3
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action.他汀类药物在新冠病毒肺炎患者中的保护作用:药代动力学特征而非作用强度的重要性。
Intern Emerg Med. 2020 Nov;15(8):1573-1576. doi: 10.1007/s11739-020-02504-y. Epub 2020 Oct 3.
4
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.住院期间使用西格列汀治疗与 COVID-19 合并 2 型糖尿病患者的死亡率降低相关:一项多中心、病例对照、回顾性、观察性研究。
Diabetes Care. 2020 Dec;43(12):2999-3006. doi: 10.2337/dc20-1521. Epub 2020 Sep 29.
5
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.意大利 DPP4 抑制剂的使用与 COVID-19 死亡病例中的糖尿病患病率无关。
Diabetes Res Clin Pract. 2021 Jan;171:108444. doi: 10.1016/j.diabres.2020.108444. Epub 2020 Sep 16.
6
Preadmission Diabetes-Specific Risk Factors for Mortality in Hospitalized Patients With Diabetes and Coronavirus Disease 2019.住院的糖尿病合并 2019 年冠状病毒病患者的死亡风险的糖尿病特定入院前危险因素。
Diabetes Care. 2020 Oct;43(10):2339-2344. doi: 10.2337/dc20-1543. Epub 2020 Aug 7.
7
Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.阿托伐他汀与入住重症监护病房的COVID-19患者死亡风险降低相关:一项回顾性队列研究。
Crit Care. 2020 Jul 14;24(1):429. doi: 10.1186/s13054-020-03154-4.
8
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.住院期间使用他汀类药物与 COVID-19 患者的死亡率降低相关。
Cell Metab. 2020 Aug 4;32(2):176-187.e4. doi: 10.1016/j.cmet.2020.06.015. Epub 2020 Jun 24.
9
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.COVID-19 合并糖尿病住院患者的表型特征和预后:CORONADO 研究。
Diabetologia. 2020 Aug;63(8):1500-1515. doi: 10.1007/s00125-020-05180-x. Epub 2020 May 29.
10
Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States.美国住院新冠病毒疾病(COVID-19)患者的血糖特征及临床结局
J Diabetes Sci Technol. 2020 Jul;14(4):813-821. doi: 10.1177/1932296820924469. Epub 2020 May 9.

糖尿病患者发生重症 COVID-19 的预测因素:一项多中心综述。

Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review.

机构信息

University of Maryland School of Medicine, Division of Endocrinology, Diabetes and Nutrition, Baltimore, Maryland.

University of Maryland Medical Center, Department of Internal Medicine, Baltimore, Maryland.

出版信息

Endocr Pract. 2021 Aug;27(8):842-849. doi: 10.1016/j.eprac.2021.05.011. Epub 2021 Jun 6.

DOI:10.1016/j.eprac.2021.05.011
PMID:34102308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8179716/
Abstract

OBJECTIVE

Diabetes is an independent risk factor for severe SARS-CoV-2 infections. This study aims to elucidate the risk factors predictive of more severe outcomes in patients with diabetes by comparing the clinical characteristics of those requiring inpatient admissions with those who remain outpatient.

METHODS

A retrospective review identified 832 patients-631 inpatients and 201 outpatients-with diabetes and a positive SARS-CoV-2 test result between March 1 and June 15, 2020. Comparisons between the outpatient and inpatient cohorts were conducted to identify risk factors associated with severity of disease determined by admission rate and mortality. Previous dipeptidyl peptidase 4 inhibitor use and disease outcomes were analyzed.

RESULTS

Risk factors for increased admission included older age (odds ratio [OR], 1.04 [95% CI, 1.01-1.06]; P = .003), the presence of chronic kidney disease (OR, 2.32 [1.26-4.28]; P = .007), and a higher hemoglobin A1c at the time of admission (OR, 1.25 [1.12-1.39]; P < .001). Lower admission rates were seen in those with commercial insurance. Increased mortality was seen in individuals with older age (OR, 1.09 [1.07-1.11]; P < .001), higher body mass index number (OR, 1.04 [1.01-1.07]; P = .003), and higher hemoglobin A1c value at the time of diagnosis of COVID-19 (OR, 1.12 [1.01-1.24]; P = .028) and patients requiring hospitalization. Lower mortality was seen in those with hyperlipidemia. Dipeptidyl peptidase 4 inhibitor use prior to COVID-19 infection was not associated with a decreased hospitalization rate.

CONCLUSION

This retrospective review offers the first analysis of outpatient predictors for admission rate and mortality of COVID-19 in patients with diabetes.

摘要

目的

糖尿病是严重 SARS-CoV-2 感染的独立危险因素。本研究旨在通过比较需要住院和门诊治疗的患者的临床特征,阐明预测糖尿病患者更严重结局的危险因素。

方法

回顾性分析了 2020 年 3 月 1 日至 6 月 15 日期间患有糖尿病和 SARS-CoV-2 检测结果阳性的 832 例患者,其中 631 例为住院患者,201 例为门诊患者。比较门诊和住院两组患者的临床特征,以确定与住院率和死亡率相关的疾病严重程度的危险因素。分析了既往二肽基肽酶 4 抑制剂的使用情况和疾病结局。

结果

住院率增加的危险因素包括年龄较大(优势比[OR],1.04[95%置信区间,1.01-1.06];P=0.003)、合并慢性肾脏病(OR,2.32[1.26-4.28];P=0.007)和入院时血红蛋白 A1c 较高(OR,1.25[1.12-1.39];P<0.001)。有商业保险的患者住院率较低。年龄较大(OR,1.09[1.07-1.11];P<0.001)、体重指数较高(OR,1.04[1.01-1.07];P=0.003)和 COVID-19 诊断时血红蛋白 A1c 值较高(OR,1.12[1.01-1.24];P=0.028)以及需要住院治疗的患者死亡率较高。患有高脂血症的患者死亡率较低。COVID-19 感染前使用二肽基肽酶 4 抑制剂与住院率降低无关。

结论

本回顾性分析首次分析了门诊患者预测糖尿病 COVID-19 住院率和死亡率的因素。